Passage Bio, Inc. (PASG) Q2 2021 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Passage Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.069 -- 00:00:05.751 Thank you for holding. Good morning and welcome to the PassageBio second quarter 2021 00:00:05.751 -- 00:00:08.652 financial and operating results conference call. 00:00:08.652 -- 00:00:11.773 At this time, all participants are in a listen-only mode. 00:00:11.773 -- 00:00:15.614 Following the formal remarks, we will open the call up for your questions. 00:00:15.614 -- 00:00:19.415 Please be advised this call is being recorded at the company's request. 00:00:19.415 -- 00:00:24.077 At this time, I would like to turn it over to Stuart Henderson, Vice President of Investor 00:00:24.077 -- 00:00:28.918 Relations and Strategic Finance. Stuart, please begin. 00:00:36.477 -- 00:00:40.940 lines to topics we plan to discuss today. This release is available on the PassageBio 00:00:40.940 -- 00:00:43.661 website at investors.passagebio.com 00:00:44.002 -- 00:00:47.424 under the Press Releases and Statements section. 00:00:47.424 -- 00:00:51.487 On today's call, Bruce Goldsmith, President and Chief Executive Officer, will review 00:00:51.487 -- 00:00:56.410 our second quarter 2021 financial results and discuss recent business highlights. 00:00:56.410 -- 00:01:01.514 Eliseo Salinas, our Chief R&D Officer, will review our key clinical updates, and Jill 00:01:01.514 -- 00:01:06.105 Quigley, Our chief operating officer will also be available for the Q&A portion of the 00:01:06.105 -- 00:01:07.706 call. 00:01:07.706 -- 00:01:11.907 Before we begin, please note that today's call may include a number of forward-looking 00:01:11.907 -- 00:01:17.008 statements, including but not limited to comments on our expectations about timing and 00:01:17.008 -- 00:01:21.530 execution of anticipated milestones, including the initiation of clinical trials and 00:01:...